Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELTA-EBV study
2025-522781-77-01Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir alafenamide in Epstein-Barr virus infection, sponsored by Helse Bergen. Primary endpoint: Treatment-emergent adverse events. Planned start May 2026; status: authorised.
02
Drugs
tenofovir alafenamide
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on 2025-522781-77-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522781-77-01.